{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:43:16Z","timestamp":1789573396964,"version":"build-2803163510"},"reference-count":171,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2021,2,9]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The technique of gene therapy, ever since its advent nearly fifty years ago, has been utilized\nby scientists as a potential treatment option for various disorders. This review discusses some of the\nmajor neurodegenerative diseases (NDDs) like Alzheimer\u2019s disease (AD), Parkinson\u2019s Disease (PD),\nMotor neuron diseases (MND), Spinal Muscular Atrophy (SMA), Huntington\u2019s Disease (HD), Multiple\nSclerosis (MS), etc. and their underlying genetic mechanisms along with the role that gene therapy\ncan play in combating them. The pathogenesis and the molecular mechanisms specifying the altered\ngene expression of each of these NDDs have also been discussed in elaboration. The use of gene therapy\nvectors can prove to be an effective tool in the field of curative modern medicine for the generations\nto come. Therefore, consistent efforts and progressive research towards its implementation can\nprovide us with powerful treatment options for disease conditions that have so far been considered as\nincurable.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523220999200817164907","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T03:32:26Z","timestamp":1597807946000},"page":"23-42","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals"],"prefix":"10.2174","volume":"21","author":[{"given":"Manisha","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida, U.P, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Bhartiya Nirdeshak Dravya Division, CSIR-National Physical Laboratory, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshikha","family":"Yadav","sequence":"additional","affiliation":[{"name":"Bhartiya Nirdeshak Dravya Division, CSIR-National Physical Laboratory, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugdha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida, U.P., India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida, U.P., India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida, U.P., India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Swargiary","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida, U.P., India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida, U.P., India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida, U.P., India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramneek","family":"Kaur","sequence":"additional","affiliation":[{"name":"School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-6962","authenticated-orcid":true,"given":"Shalini","family":"Mani","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida, U.P., India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/brainsci8090177","volume":"8","author":"Hussain R.","year":"2018","unstructured":"Hussain R.; Zubair H.; Pursell S.; Shahab M.; Neurodegenerative diseases: regenerative mechanisms and novel therapeutic approaches. Brain Sci 2018,8(9),177","journal-title":"Brain Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrg2662","volume":"10","author":"Drummond D.A.","year":"2009","unstructured":"Drummond D.A.; Wilke C.O.; The evolutionary consequences of erroneous protein synthesis. Nat Rev Genet 2009,10(10),715-724","journal-title":"Nat Rev Genet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-809813-4.00001-6","author":"Li M.","year":"2018","unstructured":"Li M.; Snider B.J.;  In: Gene therapy in neurological disorders 2018,3-39","journal-title":"In: Gene therapy in neurological disorders"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0959-4388(02)00365-3","volume":"12","author":"Washbourne P","year":"2002","unstructured":"Washbourne P; McAllister A K;  Techniques for gene transfer into neurons 2002,12(5),566-573","journal-title":"Techniques for gene transfer into neurons"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"Pardridge W.M.","year":"2020","unstructured":"Pardridge W.M.; Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci 2020,11,373-3","journal-title":"Front Aging Neurosci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"Karch C.M.","year":"2015","unstructured":"Karch C.M.; Goate A.M.; Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015,77(1),43-51","journal-title":"Biol Psychiatry"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2012.236","volume":"9","author":"Krstic D.","year":"2013","unstructured":"Krstic D.; Knuesel I.; Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013,9(1),25-34","journal-title":"Nat Rev Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"Serrano-Pozo A.","year":"2011","unstructured":"Serrano-Pozo A.; Frosch M.P.; Masliah E.; Hyman B.T.; Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011,1(1),a006189-a9","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnagi.2019.00014","volume":"11","author":"Fernandez C.G.","year":"2019","unstructured":"Fernandez C.G.; Hamby M.E.; McReynolds M.L.; Ray W.J.; The role of apoe4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer\u2019s disease. Front Aging Neurosci 2019,11,14-4","journal-title":"Front Aging Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"Dexter D.T.","year":"2013","unstructured":"Dexter D.T.; Jenner P.; Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 2013,62,132-144","journal-title":"Free Radic Biol Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.tins.2010.02.003","volume":"33","author":"Lemmens R.","year":"2010","unstructured":"Lemmens R.; Moore M.J.; Al-Chalabi A.; Brown R.H.; Robberecht W.; RNA metabolism and the pathogenesis of motor neuron diseases. Trends Neurosci 2010,33(5),249-258","journal-title":"Trends Neurosci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/nan.12014","volume":"39","author":"Gillingwater T.H.","year":"2013","unstructured":"Gillingwater T.H.; Wishart T.M.; Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease. Neuropathol Appl Neurobiol 2013,39(4),320-334","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/JEN.S33122","volume":"10","author":"Ahmad S.","year":"2016","unstructured":"Ahmad S.; Bhatia K.; Kannan A.; Gangwani L.; Molecular mechanisms of neurodegeneration in spinal muscular atrophy. J Exp Neurosci 2016,10,39-49","journal-title":"J Exp Neurosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12640-015-9573-5","volume":"29","author":"Lennon M.J.","year":"2016","unstructured":"Lennon M.J.; Jones S.P.; Lovelace M.D.; Guillemin G.J.; Brew B.J.; Bcl11b: A new piece to the complex puzzle of amyotrophic lateral sclerosis neuropathogenesis? Neurotox Res 2016,29(2),201-207","journal-title":"Neurotox Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399406010854","volume":"8","author":"Goodall E.F.","year":"2006","unstructured":"Goodall E.F.; Morrison K.E.; Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med 2006,8(11),1-22","journal-title":"Expert Rev Mol Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/ijms20184388","volume":"20","author":"Cappella M.","year":"2019","unstructured":"Cappella M.; Ciotti C.; Cohen-Tannoudji M.; Biferi M.G.; Gene Therapy for ALS-A Perspective. Int J Mol Sci 2019,20(18),4388","journal-title":"Int J Mol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","volume":"27","author":"Gil J.M.","year":"2008","unstructured":"Gil J.M.; Rego A.C.; Mechanisms of neurodegeneration in Huntington\u2019s disease. Eur J Neurosci 2008,27(11),2803-2820","journal-title":"Eur J Neurosci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s13311-013-0206-5","volume":"10","author":"Lee J.","year":"2013","unstructured":"Lee J.; Hwang Y.J.; Kim K.Y.; Kowall N.W.; Ryu H.; Epigenetic mechanisms of neurodegeneration in Huntington\u2019s disease. Neurotherapeutics 2013,10(4),664-676","journal-title":"Neurotherapeutics"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","volume":"10","author":"Friese M.A.","year":"2014","unstructured":"Friese M.A.; Schattling B.; Fugger L.; Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 2014,10(4),225-238","journal-title":"Nat Rev Neurol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","volume":"14","author":"Mahad D.H.","year":"2015","unstructured":"Mahad D.H.; Trapp B.D.; Lassmann H.; Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015,14(2),183-193","journal-title":"Lancet Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/WCO.0b013e328346056f","volume":"24","author":"Stadelmann C.","year":"2011","unstructured":"Stadelmann C.; Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol 2011,24(3),224-229","journal-title":"Curr Opin Neurol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3390\/ijms21072262","volume":"21","author":"Boia R.","year":"2020","unstructured":"Boia R.; Ruzafa N.; Aires I.D.; Neuroprotective strategies for retinal ganglion cell degeneration: current status and challenges ahead. Int J Mol Sci 2020,21(7),2262","journal-title":"Int J Mol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/1673-5374.265550","volume":"15","author":"Mirzaei M.","year":"2020","unstructured":"Mirzaei M.; Deng L.; Gupta V.B.; Graham S.; Gupta V.; Complement pathway in Alzheimer\u2019s pathology and retinal neurodegenerative disorders - the road ahead. Neural Regen Res 2020,15(2),257-258","journal-title":"Neural Regen Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ohc.2005.04.002","volume":"18","author":"Kuehn M.H.","year":"2005","unstructured":"Kuehn M.H.; Fingert J.H.; Kwon Y.H.; Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am 2005,18(3),383-395","journal-title":"Ophthalmol Clin North Am"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","volume":"17","author":"Deverman B.E.","year":"2018","unstructured":"Deverman B.E.; Ravina B.M.; Bankiewicz K.S.; Paul S.M.; Sah D.W.Y.; Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov 2018,17(9),641-659","journal-title":"Nat Rev Drug Discov"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fphar.2019.00724","volume":"10","author":"Ingusci S.","year":"2019","unstructured":"Ingusci S.; Verlengia G.; Soukupova M.; Zucchini S.; Simonato M.; Gene therapy tools for brain diseases. Front Pharmacol 2019,10,724-4","journal-title":"Front Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0971-6866.112870","volume":"19","author":"Mali S.","year":"2013","unstructured":"Mali S.; Delivery systems for gene therapy. Indian J Hum Genet 2013,19(1),3-8","journal-title":"Indian J Hum Genet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1007\/s00216-010-3821-6","volume":"397","author":"Kim T.K.","year":"2010","unstructured":"Kim T.K.; Eberwine J.H.; Mammalian cell transfection: the present and the future. Anal Bioanal Chem 2010,397(8),3173-3178","journal-title":"Anal Bioanal Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/sj.gt.3301923","volume":"9","author":"Niidome T.","year":"2002","unstructured":"Niidome T.; Huang L.; Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002,9(24),1647-1652","journal-title":"Gene Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"Yin H.","year":"2014","unstructured":"Yin H.; Kanasty R.L.; Eltoukhy A.A.; Vegas A.J.; Dorkin J.R.; Anderson D.G.; Non-viral vectors for gene-based therapy. Nat Rev Genet 2014,15(8),541-555","journal-title":"Nat Rev Genet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/pharmaceutics12020093","volume":"12","author":"Chung E.P.","year":"2020","unstructured":"Chung E.P.; Cotter J.D.; Prakapenka A.V.; Cook R.L.; DiPerna D.M.; Sirianni R.W.; Targeting small molecule delivery to the brain and spinal cord via intranasal administration of rabies virus glycoprotein (RVG29)-modified PLGA nanoparticles. Pharmaceutics 2020,12(2),93","journal-title":"Pharmaceutics"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2174\/156652306778520647","volume":"6","author":"Ivics Z.","year":"2006","unstructured":"Ivics Z.; Izsv\u00e1k Z.; Transposons for gene therapy! Curr Gene Ther 2006,6(5),593-607","journal-title":"Curr Gene Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1093\/hmg\/ddr140","volume":"20","author":"Aronovich E.L.","year":"2011","unstructured":"Aronovich E.L.; McIvor R.S.; Hackett P.B.; The sleeping beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 2011,20(R1),R14-R20","journal-title":"Hum Mol Genet"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.21037\/tcr.2016.04.02","volume":"5","author":"Zhao S.","year":"2016","unstructured":"Zhao S.; Jiang E.; Chen S.; PiggyBac transposon vectors: the tools of the human gene encoding. Transl Lung Cancer Res 2016,5(1),120-125","journal-title":"Transl Lung Cancer Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fnmol.2014.00076","volume":"7","author":"Murlidharan G.","year":"2014","unstructured":"Murlidharan G.; Samulski R.J.; Asokan A.; Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci 2014,7,76","journal-title":"Front Mol Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"Naso M.F.","year":"2017","unstructured":"Naso M.F.; Tomkowicz B.; Perry W.L.; Strohl W.R.; Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 2017,31(4),317-334","journal-title":"BioDrugs"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1101\/698506","volume":"698506.","author":"Rincon M.Y.","year":"2019","unstructured":"Rincon M.Y.; Zhou L.; Marneffe C.; AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer\u2019s disease mouse model. bioRxiv 2019,698506.","journal-title":"bioRxiv"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1093\/brain\/awz176","volume":"142","author":"Rosenblad C.","year":"2019","unstructured":"Rosenblad C.; Li Q.; Pioli E.Y.; Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson\u2019s disease. Brain 2019,142(8),2402-2416","journal-title":"Brain"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00415-018-8919-3","volume":"266","author":"Castanedo-Vazquez D.","year":"2019","unstructured":"Castanedo-Vazquez D.; Bosque-Varela P.; Sainz-Pelayo A.; Riancho J.; Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration. J Neurol 2019,266(1),27-36","journal-title":"J Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/sj.gt.3302719","volume":"13","author":"Hong C.S.","year":"2006","unstructured":"Hong C.S.; Goins W.F.; Goss J.R.; Burton E.A.; Glorioso J.C.; Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer\u2019s disease-related amyloid-beta peptide in vivo. Gene Ther 2006,13(14),1068-1079","journal-title":"Gene Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnmol.2015.00014","volume":"8","author":"Parr-Brownlie L.C.","year":"2015","unstructured":"Parr-Brownlie L.C.; Bosch-Bouju C.; Schoderboeck L.; Sizemore R.J.; Abraham W.C.; Hughes S.M.; Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms. Front Mol Neurosci 2015,8,14-4","journal-title":"Front Mol Neurosci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"Lee C.S.","year":"2017","unstructured":"Lee C.S.; Bishop E.S.; Zhang R.; Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis 2017,4(2),43-63","journal-title":"Genes Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"Daya S.","year":"2008","unstructured":"Daya S.; Berns K.I.; Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008,21(4),583-593","journal-title":"Clin Microbiol Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-61779-370-7_3","volume":"807","author":"Agbandje-McKenna M.","year":"2011","unstructured":"Agbandje-McKenna M.; Kleinschmidt J.; AAV capsid structure and cell interactions. Methods Mol Biol 2011,807,47-92","journal-title":"Methods Mol Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"14781","DOI":"10.1128\/JVI.79.23.14781-14792.2005","volume":"79","author":"Chen C.L.","year":"2005","unstructured":"Chen C.L.; Jensen R.L.; Schnepp B.C.; Molecular characterization of adeno-associated viruses infecting children. J Virol 2005,79(23),14781-14792","journal-title":"J Virol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/14712598.2012.681463","volume":"12","author":"Dayton R.D.","year":"2012","unstructured":"Dayton R.D.; Wang D.B.; Klein R.L.; The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther 2012,12(6),757-766","journal-title":"Expert Opin Biol Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"07502","DOI":"10.1016\/j.biotechadv.2019.107502","volume":"401","author":"Ma C-C.","year":"2020","unstructured":"Ma C-C.; Wang Z-L.; Xu T.; He Z-Y.; Wei Y-Q.; The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv 2020,401,07502","journal-title":"Biotechnol Adv"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/aas.12821","volume":"61","author":"Liu H.","year":"2017","unstructured":"Liu H.; Tariq R.; Liu G.L.; Yan H.; Kaye A.D.; Inadvertent intrathecal injections and best practice management. Acta Anaesthesiol Scand 2017,61(1),11-22","journal-title":"Acta Anaesthesiol Scand"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/hmg\/ddl069","volume":"15","author":"Ding J.","year":"2006","unstructured":"Ding J.; Allen E.; Wang W.; Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport. Hum Mol Genet 2006,15(9),1451-1463","journal-title":"Hum Mol Genet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"30675","DOI":"10.18632\/oncotarget.5169","volume":"6","author":"Chira S.","year":"2015","unstructured":"Chira S.; Jackson C.S.; Oprea I.; Progresses towards safe and efficient gene therapy vectors. Oncotarget 2015,6(31),30675-30703","journal-title":"Oncotarget"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jgm.861","volume":"8","author":"Fedorova E.","year":"2006","unstructured":"Fedorova E.; Battini L.; Prakash-Cheng A.; Marras D.; Gusella G.L.; Lentiviral gene delivery to CNS by spinal intrathecal administration to neonatal mice. J Gene Med 2006,8(4),414-424","journal-title":"J Gene Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2016.10.022","volume":"67","author":"Cohen-Pfeffer J.L.","year":"2017","unstructured":"Cohen-Pfeffer J.L.; Gururangan S.; Lester T.; Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol 2017,67,23-35","journal-title":"Pediatr Neurol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1182\/blood-2012-07-440974","volume":"121","author":"Rubenstein J.L.","year":"2013","unstructured":"Rubenstein J.L.; Li J.; Chen L.; Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood 2013,121(5),745-751","journal-title":"Blood"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.taap.2014.03.005","volume":"277","author":"Vuillemenot B.R.","year":"2014","unstructured":"Vuillemenot B.R.; Kennedy D.; Reed R.P.; Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution. Toxicol Appl Pharmacol 2014,277(1),49-57","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=55","author":"","year":"2013","unstructured":"; A Phase 1\/2 open-label dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and efficacy of intracerebroventricular BMN 190 in patients with late-infantile neuronal ceroid lipofuscinosis (CLN2) disease. U.S. Patent NCT01907087, 2013"},{"key":"ref=56","year":"2011","unstructured":"An open label, safety and tolerability continuation study of intracerebroventricular administration of snn0029 to patients with amyotrophic lateral sclerosis. U.S. Patent NCT01384162, 2011"},{"key":"ref=57","year":"2015","unstructured":"Study on tolerability of repeat I.C.V. administration of sNN0031 infusion solution in patients with PD. US Patent NCT02408562, 2015"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.neuropharm.2012.11.015","volume":"68","author":"Millan M.J.","year":"2013","unstructured":"Millan M.J.; An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology 2013,68,2-82","journal-title":"Neuropharmacology"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41401-019-0338-1","volume":"41","author":"Li R.","year":"2020","unstructured":"Li R.; Li D.H.; Zhang H.Y.; Wang J.; Li X.K.; Xiao J.; Growth factors-based therapeutic strategies and their underlying signaling mechanisms for peripheral nerve regeneration. Acta Pharmacol 2020,41,1289-1300","journal-title":"Acta Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mcn.2018.03.013","volume":"91","author":"Scott-Solomon E.","year":"2018","unstructured":"Scott-Solomon E.; Kuruvilla R.; Mechanisms of neurotrophin trafficking via Trk receptors. Mol Cell Neurosci 2018,91,25-33","journal-title":"Mol Cell Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"16034","DOI":"10.1038\/mtm.2016.34","volume":"3","author":"Kumar S.R.","year":"2016","unstructured":"Kumar S.R.; Markusic D.M.; Biswas M.; High K.A.; Herzog R.W.; Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016,3,16034-4","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1517\/17425247.2014.882314","volume":"11","author":"Kouprina N.","year":"2014","unstructured":"Kouprina N.; Tomilin A.N.; Masumoto H.; Earnshaw W.C.; Larionov V.; Human artificial chromosome-based gene delivery vectors for biomedicine and biotechnology. Expert Opin Drug Deliv 2014,11(4),517-535","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/mt.2011.136","volume":"19","author":"Kazuki Y.","year":"2011","unstructured":"Kazuki Y.; Oshimura M.; Human artificial chromosomes for gene delivery and the development of animal models. Mol Ther 2011,19(9),1591-1601","journal-title":"Mol Ther"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3389\/fphys.2019.00486","volume":"10","author":"P\u00f6yh\u00f6nen S.","year":"2019","unstructured":"P\u00f6yh\u00f6nen S.; Er S.; Domanskyi A.; Airavaara M.; Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury. Front Physiol 2019,10,486","journal-title":"Front Physiol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"Daya S","year":"2008","unstructured":"Daya S; Berns K I J C mr.; Gene therapy using adeno-associated virus vectors 2008,21(4),583-93"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3389\/fphys.2019.00486","volume":"10","author":"P\u00f6yh\u00f6nen S.","year":"2019","unstructured":"P\u00f6yh\u00f6nen S.; Er S.; Domanskyi A.; Airavaara M.; Effects of neurotrophic factors in glial cells in the central nervous system: expression and properties in neurodegeneration and injury. Front Physiol 2019,10,486-6","journal-title":"Front Physiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1089\/104303402760128612","volume":"13","author":"Janson C.","year":"2002","unstructured":"Janson C.; McPhee S.; Bilaniuk L.; Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002,13(11),1391-1412","journal-title":"Hum Gene Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-016-0195-9","volume":"8","author":"Eyjolfsdottir H.","year":"2016","unstructured":"Eyjolfsdottir H.; Eriksdotter M.; Linderoth B.; Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer\u2019s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimers Res Ther 2016,8(1),30","journal-title":"Alzheimers Res Ther"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2018.11.39","volume":"6","author":"Sun A.","year":"2018","unstructured":"Sun A.; Lysosomal storage disease overview. Ann Transl Med 2018,6(24),476-6","journal-title":"Ann Transl Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","volume":"9","author":"Bailey R.M.","year":"2018","unstructured":"Bailey R.M.; Armao D.; Nagabhushan Kalburgi S.; Gray S.J.; Development of intrathecal AAV9 gene therapy for giant axonal neuropathy. Mol Ther Methods Clin Dev 2018,9,160-171","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fmolb.2020.00057","volume":"7","author":"Favret J.M.","year":"2020","unstructured":"Favret J.M.; Weinstock N.I.; Feltri M.L.; Shin D.; Pre-clinical mouse models of neurodegenerative lysosomal storage diseases. Front Mol Biosci 2020,7,57","journal-title":"Front Mol Biosci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1093\/hmg\/ddv168","volume":"24","author":"Weismann C.M.","year":"2015","unstructured":"Weismann C.M.; Ferreira J.; Keeler A.M.; Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan. Hum Mol Genet 2015,24(15),4353-4364","journal-title":"Hum Mol Genet"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/mt.2014.135","volume":"22","author":"Hinderer C.","year":"2014","unstructured":"Hinderer C.; Bell P.; Gurda B.L.; Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther 2014,22(12),2018-2027","journal-title":"Mol Ther"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ymgmr.2015.11.006","volume":"6","author":"Gilkes J.A.","year":"2015","unstructured":"Gilkes J.A.; Bloom M.D.; Heldermon C.D.; Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes. Mol Genet Metab Rep 2015,6,48-54","journal-title":"Mol Genet Metab Rep"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ymgme.2015.05.003","volume":"116","author":"Gray-Edwards H.L.","year":"2015","unstructured":"Gray-Edwards H.L.; Brunson B.L.; Holland M.; Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy. Mol Genet Metab 2015,116(1-2),80-87","journal-title":"Mol Genet Metab"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/gt.2014.17","volume":"21","author":"Miyake N.","year":"2014","unstructured":"Miyake N.; Miyake K.; Asakawa N.; Yamamoto M.; Shimada T.; Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector. Gene Ther 2014,21(4),427-433","journal-title":"Gene Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.gene.2015.06.049","volume":"571","author":"Lin D-S.","year":"2015","unstructured":"Lin D-S.; Hsiao C-D.; Lee A.Y-L.; Mitigation of cerebellar neuropathy in globoid cell leukodystrophy mice by AAV-mediated gene therapy. Gene 2015,571(1),81-90","journal-title":"Gene"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3892\/etm.2019.7760","volume":"18","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; Chen X.; Liu C.; Metachromatic leukodystrophy: Characterization of two (p.Leu433Val, p.Gly449Arg) arylsulfatase A mutations. Exp Ther Med 2019,18(3),1738-1744","journal-title":"Exp Ther Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/85454","volume":"7","author":"Consiglio A.","year":"2001","unstructured":"Consiglio A.; Quattrini A.; Martino S.; In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med 2001,7(3),310-316","journal-title":"Nat Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/jnr.23792","volume":"94","author":"Rosenberg J.B.","year":"2016","unstructured":"Rosenberg J.B.; Kaminsky S.M.; Aubourg P.; Crystal R.G.; Sondhi D.; Gene therapy for metachromatic leukodystrophy. J Neurosci Res 2016,94(11),1169-1179","journal-title":"J Neurosci Res"},{"key":"ref=81","doi-asserted-by":"publisher","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch7","author":"Zahoor I.","year":"2018","unstructured":"Zahoor I.; Shafi A.; Haq E.; Pharmacological treatment of parkinson\u2019s disease.parkinson\u2019s disease: pathogenesis and clinical aspects; Stoker TB, Greenland JC, Eds Brisbane (AU). 2018"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.omtm.2019.07.002","volume":"14","author":"Badin R.A.","year":"2019","unstructured":"Badin R.A.; Binley K.; Van Camp N.; Gene therapy for parkinson\u2019s disease: preclinical evaluation of optimally configured th:ch1 fusion for maximal dopamine synthesis. Mol Ther Methods Clin Dev 2019,14,206-216","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"Palfi S.","year":"2014","unstructured":"Palfi S.; Gurruchaga J.M.; Ralph G.S.; Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 2014,383(9923),1138-1146","journal-title":"Lancet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"Agrawal N.","year":"2003","unstructured":"Agrawal N.; Dasaradhi P.V.N.; Mohmmed A.; Malhotra P.; Bhatnagar R.K.; Mukherjee S.K.; RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 2003,67(4),657-685","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.gt.3302405","volume":"12","author":"Golzio M.","year":"2005","unstructured":"Golzio M.; Mazzolini L.; Moller P.; Rols M.P.; Teissi\u00e9 J.; Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther 2005,12(3),246-251","journal-title":"Gene Ther"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/ijms18040754","volume":"18","author":"Kolli N.","year":"2017","unstructured":"Kolli N.; Lu M.; Maiti P.; Rossignol J.; Dunbar G.L.; CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an in vitro model of huntington\u2019s disease. Int J Mol Sci 2017,18(4),754","journal-title":"Int J Mol Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"Stanek L.M.","year":"2014","unstructured":"Stanek L.M.; Sardi S.P.; Mastis B.; Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum Gene Ther 2014,25(5),461-474","journal-title":"Hum Gene Ther"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/mt.2008.50","volume":"16","author":"Franich N.R.","year":"2008","unstructured":"Franich N.R.; Fitzsimons H.L.; Fong D.M.; Klugmann M.; During M.J.; Young D.; AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease. Mol Ther 2008,16(5),947-956","journal-title":"Mol Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"Pfister E.L.","year":"2009","unstructured":"Pfister E.L.; Kennington L.; Straubhaar J.; Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol 2009,19(9),774-778","journal-title":"Curr Biol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molmed.2004.06.009","volume":"10","author":"Bendotti C.","year":"2004","unstructured":"Bendotti C.; Carr\u00ec M.T.; Lessons from models of SOD1-linked familial ALS. Trends Mol Med 2004,10(8),393-400","journal-title":"Trends Mol Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.neuron.2006.09.018","volume":"52","author":"Boill\u00e9e S.","year":"2006","unstructured":"Boill\u00e9e S.; Vande Velde C.; Cleveland D.W.; ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006,52(1),39-59","journal-title":"Neuron"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrn1971","volume":"7","author":"Pasinelli P.","year":"2006","unstructured":"Pasinelli P.; Brown R.H.; Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006,7(9),710-723","journal-title":"Nat Rev Neurosci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1212\/WNL.53.6.1239","volume":"53","author":"Shefner J.M.","year":"1999","unstructured":"Shefner J.M.; Reaume A.G.; Flood D.G.; Mice lacking cytosolic copper\/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology 1999,53(6),1239-1246","journal-title":"Neurology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14304\/SURYA.JPR.V4N7.5","volume":"4","author":"Chery J.","year":"2016","unstructured":"Chery J.; RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J 2016,4(7),35-50","journal-title":"Postdoc J"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"McCampbell A.","year":"2018","unstructured":"McCampbell A.; Cole T.; Wegener A.J.; Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest 2018,128(8),3558-3567","journal-title":"J Clin Invest"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/WCO.0000000000000594","volume":"31","author":"Ly C.V.","year":"2018","unstructured":"Ly C.V.; Miller T.M.; Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr Opin Neurol 2018,31(5),648-654","journal-title":"Curr Opin Neurol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/mt.2016.10","volume":"24","author":"Maeder M.L.","year":"2016","unstructured":"Maeder M.L.; Gersbach C.A.; Genome-editing technologies for gene and cell therapy. Mol Ther 2016,24(3),430-446","journal-title":"Mol Ther"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"Gaj T.","year":"2013","unstructured":"Gaj T.; Gersbach C.A.; Barbas C.F.; ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol 2013,31(7),397-405","journal-title":"Trends Biotechnol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-genet-112414-054926","volume":"49","author":"Hotta A.","year":"2015","unstructured":"Hotta A.; Yamanaka S.; From genomics to gene therapy: induced pluripotent stem cells meet genome editing. Annu Rev Genet 2015,49,47-70","journal-title":"Annu Rev Genet"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192497","volume":"13","author":"Marrone L.","year":"2018","unstructured":"Marrone L.; Bus C.; Sch\u00f6ndorf D.; Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson\u2019s disease. PLoS One 2018,13(3)","journal-title":"PLoS One"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/mt.2014.234","volume":"23","author":"Ousterout D.G.","year":"2015","unstructured":"Ousterout D.G.; Kabadi A.M.; Thakore P.I.; Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Therap 2015,23(3),523-532","journal-title":"Mol Therap"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3389\/fpls.2017.01919","volume":"8","author":"Huang R.","year":"2017","unstructured":"Huang R.; Hui S.; Zhang M.; A conserved basal transcription factor is required for the function of diverse tal effectors in multiple plant hosts. Front Plant Sci 2017,8,1919-9","journal-title":"Front Plant Sci"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"Lino C.A.","year":"2018","unstructured":"Lino C.A.; Harper J.C.; Carney J.P.; Timlin J.A.; Delivering CRISPR: a review of the challenges and approaches. Drug Deliv 2018,25(1),1234-1257","journal-title":"Drug Deliv"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1093\/mp\/sst121","volume":"6","author":"Mao Y.","year":"2013","unstructured":"Mao Y.; Zhang H.; Xu N.; Zhang B.; Gou F.; Zhu J-K.; Application of the CRISPR-Cas system for efficient genome engineering in plants. Mol Plant 2013,6(6),2008-2011","journal-title":"Mol Plant"},{"key":"ref=105","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2011.5","author":"Carlson DF","year":"2012","unstructured":"Carlson DF; Fahrenkrug SC; Hackett PB;  Targeting DNA with fingers and TALENs Mol Ther Nucleic Acids 1e32012","journal-title":"Targeting DNA with fingers and TALENs Mol Ther Nucleic Acids"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrg3686","volume":"15","author":"Kim H.","year":"2014","unstructured":"Kim H.; Kim J-S.; A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014,15(5),321-334","journal-title":"Nat Rev Genet"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.biocel.2013.10.010","volume":"46","author":"Zhou J.","year":"2014","unstructured":"Zhou J.; Shen B.; Zhang W.; One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR\/Cas9 mediated genome engineering. Int J Biochem Cell Biol 2014,46,49-55","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089413","volume":"9","author":"Ma Y.","year":"2014","unstructured":"Ma Y.; Shen B.; Zhang X.; Heritable multiplex genetic engineering in rats using CRISPR\/Cas9. PLoS One 2014,9(3)","journal-title":"PLoS One"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","volume":"25","author":"Nelson C.E.","year":"2019","unstructured":"Nelson C.E.; Wu Y.; Gemberling M.P.; Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med 2019,25(3),427-432","journal-title":"Nat Med"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","volume":"17","author":"Ekman F.K.","year":"2019","unstructured":"Ekman F.K.; Ojala D.S.; Adil M.M.; Lopez P.A.; Schaffer D.V.; Gaj T.; CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s disease mouse model. Mol Ther Nucleic Acids 2019,17,829-839","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/104303403321070874","volume":"14","author":"DiDonato C.J.","year":"2003","unstructured":"DiDonato C.J.; Parks R.J.; Kothary R.; Development of a gene therapy strategy for the restoration of survival motor neuron protein expression: implications for spinal muscular atrophy therapy. Hum Gene Ther 2003,14(2),179-188","journal-title":"Hum Gene Ther"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/sj.gt.3301550","volume":"8","author":"Zhang M-L.","year":"2001","unstructured":"Zhang M-L.; Lorson C.L.; Androphy E.J.; Zhou J.; An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 2001,8(20),1532-1538","journal-title":"Gene Ther"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-89689-2_2","volume":"20","author":"Singh R.N.","year":"2018","unstructured":"Singh R.N.; Singh N.N.; Mechanism of splicing regulation of spinal muscular atrophy genes. Adv Neurobiol 2018,20,31-61","journal-title":"Adv Neurobiol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.4155\/fmc.12.131","volume":"4","author":"Lorson M.A.","year":"2012","unstructured":"Lorson M.A.; Lorson C.L.; SMN-inducing compounds for the treatment of spinal muscular atrophy. Future Med Chem 2012,4(16),2067-2084","journal-title":"Future Med Chem"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1126\/science.2660259","volume":"244","author":"Friedmann T.","year":"1989","unstructured":"Friedmann T.; Progress toward human gene therapy. Science 1989,244(4910),1275-1281","journal-title":"Science"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1172\/JCI121658","volume":"128","author":"Sumner C.J.","year":"2018","unstructured":"Sumner C.J.; Crawford T.O.; Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest 2018,128(8),3219-3227","journal-title":"J Clin Invest"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/ar361","volume":"3","author":"Gouze-Decaris E.","year":"2001","unstructured":"Gouze-Decaris E.; Pawliuk R.; Pilapil C.; Leboulch P.; Evans C.H.; Ghivizzani S.C.; In vitro and in vivo gene delivery using a lentiviral vector. Arthritis Res 2001,3(Suppl. 1),34-P34","journal-title":"Arthritis Res"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/emmm.201202305","volume":"5","author":"Cherry J.J.","year":"2013","unstructured":"Cherry J.J.; Osman E.Y.; Evans M.C.; Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol Med 2013,5(7),1103-1118","journal-title":"EMBO Mol Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"Oddo S.","year":"2003","unstructured":"Oddo S.; Caccamo A.; Shepherd J.D.; Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003,39(3),409-421","journal-title":"Neuron"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1073\/pnas.0409072102","volume":"102","author":"Dodart J.C.","year":"2005","unstructured":"Dodart J.C.; Marr R.A.; Koistinaho M.; Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 2005,102(4),1211-1216","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/1673-5374.224362","volume":"13","author":"Onyango I.G.","year":"2018","unstructured":"Onyango I.G.; Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer\u2019s disease. Neural Regen Res 2018,13(1),19-25","journal-title":"Neural Regen Res"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"177","DOI":"10.21037\/atm.2018.04.20","volume":"6","author":"Wang M-M.","year":"2018","unstructured":"Wang M-M.; Miao D.; Cao X-P.; Tan L.; Tan L.; Innate immune activation in Alzheimer\u2019s disease. Ann Transl Med 2018,6(10),177","journal-title":"Ann Transl Med"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"Saadoun D.","year":"2011","unstructured":"Saadoun D.; Rosenzwajg M.; Joly F.; Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011,365(22),2067-2077","journal-title":"N Engl J Med"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/brain\/awx109","volume":"140","author":"Alves S.","year":"2017","unstructured":"Alves S.; Churlaud G.; Audrain M.; Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer\u2019s disease mice. Brain 2017,140(3),826-842","journal-title":"Brain"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","volume":"44","author":"Zhao L.","year":"2016","unstructured":"Zhao L.; Gottesdiener A.J.; Parmar M.; Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models. Neurobiol Aging 2016,44,159-172","journal-title":"Neurobiol Aging"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12035-018-1068-y","volume":"56","author":"Raikwar S.P.","year":"2019","unstructured":"Raikwar S.P.; Thangavel R.; Dubova I.; Targeted gene editing of glia maturation factor in microglia: a novel Alzheimer\u2019s disease therapeutic target. Mol Neurobiol 2019,56(1),378-393","journal-title":"Mol Neurobiol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/02648725.2018.1523521","volume":"35","author":"Sasmita A.O.","year":"2019","unstructured":"Sasmita A.O.; Current viral-mediated gene transfer research for treatment of Alzheimer\u2019s disease. Biotechnol Genet Eng Rev 2019,35(1),26-45","journal-title":"Biotechnol Genet Eng Rev"},{"key":"ref=128","first-page":"24","volume":"29","author":"Rosenberg JB","year":"2018","unstructured":"Rosenberg JB; Kaplitt MG; De BP; 10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer's disease 2018,29(1),24-47"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.molmed.2015.06.001","volume":"21","author":"O\u2019Connor D.M.","year":"2015","unstructured":"O\u2019Connor D.M.; Boulis N.M.; Gene therapy for neurodegenerative diseases. Trends Mol Med 2015,21(8),504-512","journal-title":"Trends Mol Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/mt.2013.281","volume":"22","author":"Bartus R.T.","year":"2014","unstructured":"Bartus R.T.; Weinberg M.S.; Samulski R.J.; Parkinson\u2019s disease gene therapy: success by design meets failure by efficacy. Mol Ther 2014,22(3),487-497","journal-title":"Mol Ther"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"Mittermeyer G.","year":"2012","unstructured":"Mittermeyer G.; Christine C.W.; Rosenbluth K.H.; Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum Gene Ther 2012,23(4),377-381","journal-title":"Hum Gene Ther"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.nbd.2009.07.022","volume":"36","author":"Emborg M.E.","year":"2009","unstructured":"Emborg M.E.; Moirano J.; Raschke J.; Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 2009,36(2),303-311","journal-title":"Neurobiol Dis"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nbd.2013.04.011","volume":"58","author":"Herzog C.D.","year":"2013","unstructured":"Herzog C.D.; Brown L.; Kruegel B.R.; Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol Dis 2013,58,38-48","journal-title":"Neurobiol Dis"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"Warren Olanow C.","year":"2015","unstructured":"Warren Olanow C.; Bartus R.T.; Baumann T.L.; Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol 2015,78(2),248-257","journal-title":"Ann Neurol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"LeWitt P.A.","year":"2011","unstructured":"LeWitt P.A.; Rezai A.R.; Leehey M.A.; AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011,10(4),309-319","journal-title":"Lancet Neurol"},{"key":"ref=136","first-page":"35","volume":"13","author":"Nicolson G.L.","year":"2014","unstructured":"Nicolson G.L.; Mitochondrial dysfunction and chronic disease: treatment with natural supplements. Integr Med (Encinitas) 2014,13(4),35-43","journal-title":"Integr Med (Encinitas)"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1745017901814010089","volume":"14","author":"Oliveira de Carvalho A.","year":"2018","unstructured":"Oliveira de Carvalho A.; Filho A.S.S.; Murillo-Rodriguez E.; Rocha N.B.; Carta M.G.; Machado S.; Physical exercise for parkinson\u2019s disease: clinical and experimental evidence. Clin Pract Epidemiol Ment Health 2018,14,89-98","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"Burghes A.H.M.","year":"2009","unstructured":"Burghes A.H.M.; Beattie C.E.; Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 2009,10(8),597-609","journal-title":"Nat Rev Neurosci"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1523\/JNEUROSCI.2728-12.2013","volume":"33","author":"Branchu J.","year":"2013","unstructured":"Branchu J.; Biondi O.; Chali F.; Shift from extracellular signal-regulated kinase to AKT\/cAMP response element-binding protein pathway increases survival-motor-neuron expression in spinal-muscular-atrophy-like mice and patient cells. J Neurosci 2013,33(10),4280-4294","journal-title":"J Neurosci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.4155\/fmc.14.63","volume":"6","author":"Howell M.D.","year":"2014","unstructured":"Howell M.D.; Singh N.N.; Singh R.N.; Advances in therapeutic development for spinal muscular atrophy. Future Med Chem 2014,6(9),1081-1099","journal-title":"Future Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s13311-014-0293-y","volume":"11","author":"Awano T.","year":"2014","unstructured":"Awano T.; Kim J-K.; Monani U.R.; Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics 2014,11(4),786-795","journal-title":"Neurotherapeutics"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.4155\/fmc.15.101","volume":"7","author":"Singh N.N.","year":"2015","unstructured":"Singh N.N.; Lee B.M.; DiDonato C.J.; Singh R.N.; Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy. Future Med Chem 2015,7(13),1793-1808","journal-title":"Future Med Chem"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-1-62703-980-2_20","volume":"1126","author":"Seo J.","year":"2014","unstructured":"Seo J.; Ottesen E.W.; Singh R.N.; Antisense methods to modulate pre-mRNA splicing. Methods Mol Biol 2014,1126,271-283","journal-title":"Methods Mol Biol"},{"key":"ref=144","author":"Singh R.N.","year":"2010","unstructured":"Singh R.N.; Singh N.N.; Singh N.K.; Androphy E.J.; Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences U.S. Patent 20190292540, 2010"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"Singh N.K.","year":"2006","unstructured":"Singh N.K.; Singh N.N.; Androphy E.J.; Singh R.N.; Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006,26(4),1333-1346","journal-title":"Mol Cell Biol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","volume":"26","author":"Pattali R.","year":"2019","unstructured":"Pattali R.; Mou Y.; Li X-J.; AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. Gene Ther 2019,26(7-8),287-295","journal-title":"Gene Ther"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"Hinderer C.","year":"2018","unstructured":"Hinderer C.; Katz N.; Buza E.L.; Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther 2018,29(3),285-298","journal-title":"Hum Gene Ther"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"Foust K.D.","year":"2010","unstructured":"Foust K.D.; Wang X.; McGovern V.L.; Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010,28(3),271-274","journal-title":"Nat Biotechnol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI41615","volume":"120","author":"Passini M.A.","year":"2010","unstructured":"Passini M.A.; Bu J.; Roskelley E.M.; CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010,120(4),1253-1264","journal-title":"J Clin Invest"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"Valori C.F.","year":"2010","unstructured":"Valori C.F.; Ning K.; Wyles M.; Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010,2(35),35ra42-2","journal-title":"Sci Transl Med"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"Mendell J.R.","year":"2017","unstructured":"Mendell J.R.; Al-Zaidy S.; Shell R.; Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017,377(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.tips.2018.09.001","volume":"39","author":"Li D.","year":"2018","unstructured":"Li D.; Mastaglia F.L.; Fletcher S.; Wilton S.D.; Precision medicine through antisense oligonucleotide-mediated exon skipping. Trends Pharmacol Sci 2018,39(11),982-994","journal-title":"Trends Pharmacol Sci"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"Stein C.A.","year":"2017","unstructured":"Stein C.A.; Castanotto D.; FDA-approved oligonucleotide therapies in 2017. Mol Ther 2017,25(5),1069-1075","journal-title":"Mol Ther"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1566523217666171013124150","volume":"17","author":"Donde A.","year":"2017","unstructured":"Donde A.; Wong P.C.; Chen L.L.; Challenges and advances in gene therapy approaches for neurodegenerative disorders. Curr Gene Ther 2017,17(3),187-193","journal-title":"Curr Gene Ther"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"Hoy S.M.","year":"2019","unstructured":"Hoy S.M.; Onasemnogene abeparvovec: first global approval. Drugs 2019,79(11),1255-1262","journal-title":"Drugs"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","volume":"36","author":"Dabbous O.","year":"2019","unstructured":"Dabbous O.; Maru B.; Jansen J.P.; Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther 2019,36(5),1164-1176","journal-title":"Adv Ther"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.yexcr.2006.02.021","volume":"312","author":"Wootz H.","year":"2006","unstructured":"Wootz H.; Hansson I.; Korhonen L.; Lindholm D.; XIAP decreases caspase-12 cleavage and calpain activity in spinal cord of ALS transgenic mice. Exp Cell Res 2006,312(10),1890-1898","journal-title":"Exp Cell Res"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature02544","volume":"429","author":"Azzouz M.","year":"2004","unstructured":"Azzouz M.; Ralph G.S.; Storkebaum E.; VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004,429(6990),413-417","journal-title":"Nature"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnins.2010.00032","volume":"4","author":"Henriques A.","year":"2010","unstructured":"Henriques A.; Pitzer C.; Schneider A.; Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci 2010,4,32-2","journal-title":"Front Neurosci"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12031-015-0695-2","volume":"58","author":"Benkler C.","year":"2016","unstructured":"Benkler C.; Barhum Y.; Ben-Zur T.; Offen D.; Multifactorial gene therapy enhancing the glutamate uptake system and reducing oxidative stress delays symptom onset and prolongs survival in the SOD1-G93A ALS mouse model. J Mol Neurosci 2016,58(1),46-58","journal-title":"J Mol Neurosci"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","volume":"25","author":"Biferi M.G.","year":"2017","unstructured":"Biferi M.G.; Cohen-Tannoudji M.; Cappelletto A.; A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model. Mol Ther 2017,25(9),2038-2052","journal-title":"Mol Ther"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/hmg\/5.5.591","volume":"5","author":"Ali R.R.","year":"1996","unstructured":"Ali R.R.; Reichel M.B.; Thrasher A.J.; Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 1996,5(5),591-594","journal-title":"Hum Mol Genet"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1073\/pnas.94.13.6916","volume":"94","author":"Flannery J.G.","year":"1997","unstructured":"Flannery J.G.; Zolotukhin S.; Vaquero M.I.; LaVail M.M.; Muzyczka N.; Hauswirth W.W.; Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997,94(13),6916-6921","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.gt.3300440","volume":"4","author":"Jomary C.","year":"1997","unstructured":"Jomary C.; Vincent K.A.; Grist J.; Neal M.J.; Jones S.E.; Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther 1997,4(7),683-690","journal-title":"Gene Ther"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"12413","DOI":"10.1073\/pnas.0503460102","volume":"102","author":"Moiseyev G.","year":"2005","unstructured":"Moiseyev G.; Chen Y.; Takahashi Y.; Wu B.X.; Ma J.X.; RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci USA 2005,102(35),12413-12418","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1089\/hum.2008.107","volume":"19","author":"Hauswirth W.W.","year":"2008","unstructured":"Hauswirth W.W.; Aleman T.S.; Kaushal S.; Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008,19(10),979-990","journal-title":"Hum Gene Ther"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"Maguire A.M.","year":"2008","unstructured":"Maguire A.M.; Simonelli F.; Pierce E.A.; Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N Engl J Med 2008,358(21),2240-2248","journal-title":"N Engl J Med"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnins.2017.00174","volume":"11","author":"Ochakovski G.A.","year":"2017","unstructured":"Ochakovski G.A.; Bartz-Schmidt K.U.; Fischer M.D.; Retinal gene therapy: surgical vector delivery in the translation to clinical trials. Front Neurosci 2017,11,174-4","journal-title":"Front Neurosci"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","volume":"10","author":"Yang S.","year":"2016","unstructured":"Yang S.; Ma S.Q.; Wan X.; Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy. EBioMedicine 2016,10,258-268","journal-title":"EBioMedicine"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","volume":"124","author":"Guy J.","year":"2017","unstructured":"Guy J.; Feuer W.J.; Davis J.L.; Gene therapy for Leber hereditary optic neuropathy: low-and medium-dose visual results. Ophthalmology 2017,124(11),1621-1634","journal-title":"Ophthalmology"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1167\/iovs.16-19754","volume":"57","author":"Roh Y.J.","year":"2016","unstructured":"Roh Y.J.; Rho C.R.; Cho W-K.; Kang S.; Science, V. The antiangiogenic effects of gold nanoparticles on experimental choroidal neovascularization in mice. Invest Ophthalmol Vis Sci 2016,57(15),6561-6567","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184940\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T10:04:14Z","timestamp":1637057054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184940\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":171,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523220999200817164907","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}